Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

54.6K
Overview
54.6K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
Allergic Reactions02:06

Allergic Reactions

34.1K
Overview
34.1K
Vaccines01:21

Vaccines

53
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
53
Cross-reactivity00:42

Cross-reactivity

34.0K
Overview
34.0K
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

207
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
207

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biphasic Effects on Allergen-Specific Type 2 Memory B Cells Over 18 Months Sublingual Immunotherapy for House Dust Mite Allergy.

Allergy·2026
Same author

Availability and Costs of Allergic Rhinitis Treatments Across the World: A Survey of ARIA Experts.

Allergy·2026
Same author

Three-dose COVID-19 vaccination elicits immune memory in patients with inborn errors of immunity even in the absence of neutralizing antibodies.

The Journal of allergy and clinical immunology·2026
Same author

Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part II-Guidelines on Oral and Ocular Treatments.

Allergy·2026
Same author

Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part I-Guidelines on Intranasal Treatments.

Allergy·2025
Same author

Novel SYK Variant Causes Enhanced SYK Autophosphorylation and PI3K Activation in an Antibody-Deficient Patient.

Journal of clinical immunology·2025

Related Experiment Video

Updated: Apr 11, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.2K

Current developments for improving efficacy of allergy vaccines.

Alessandra Sandrini1, Jennifer M Rolland, Robyn E O'Hehir

  • 1Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Monash University, Melbourne, Victoria, Australia.

Expert Review of Vaccines
|May 28, 2015
PubMed
Summary

Allergen immunotherapy (AIT) offers disease modification for allergies. Research focuses on safer, more effective AIT methods, including epitope-based peptides and recombinant allergens, to improve long-term immune tolerance.

Keywords:
T-cell anergyT-cell epitope peptideTregadjuvantallergen immunotherapyallergic rhinitisallergy vaccineasthmarecombinant allergensublingual immunotherapy

More Related Videos

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

4.1K
Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

13.0K

Related Experiment Videos

Last Updated: Apr 11, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.2K
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

4.1K
Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

13.0K

Area of Science:

  • Immunology
  • Allergy Research
  • Vaccinology

Background:

  • Allergic diseases affect a significant global population.
  • Allergen immunotherapy (AIT) modifies disease course via Treg cells, IL-10, TGF-β, and IgG4 antibodies.
  • Current AIT methods (subcutaneous, sublingual) face limitations in convenience, safety, and patient eligibility.

Purpose of the Study:

  • To review the current status of allergen immunotherapy (AIT).
  • To discuss recent advances aimed at enhancing AIT efficacy, safety, and long-term immune tolerance.
  • To explore novel AIT strategies addressing current limitations.

Main Methods:

  • Review of existing literature on allergen immunotherapy.
  • Analysis of emerging AIT approaches, including T-cell epitope-based peptides and recombinant allergen derivatives.
  • Exploration of alternative administration routes, adjuvants, and adjunct therapies.

Main Results:

  • New AIT forms are under investigation to improve safety and immunogenicity.
  • Strategies include reducing allergenicity while enhancing immune response.
  • Advances focus on T-cell epitope-based peptides and recombinant allergens.

Conclusions:

  • Significant progress is being made in developing more efficacious, convenient, and safer AIT options.
  • Future AIT strategies aim for improved clinical outcomes and sustained immune tolerance.
  • Ongoing research addresses limitations of current AIT for broader application.